Association of smoking and drug abuse with treatment failure  in individuals with tuberculosis: a case-control study by Serpoosh, Homa et al.
ORIGINAL RESEARCHES
383www.journals.viamedica.pl




Copyright © 2020 PTChP
ISSN 2451–4934
Homa Serpoosh1, 2, Yadollah Hamidi1, Payman Eini3, Younes Mohammadi4, 5
1Department of Health Economy and Management, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
2Students Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
3Department of Infectious Disease, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
4Social Determinants of Health Research Center, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
5Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
Association of smoking and drug abuse with treatment failure 
in individuals with tuberculosis: a case-control study
Abstract
Introduction: Treatment failure in tuberculosis (defined as a positive sputum smear 5 months after the initiation of anti-TB treat-
ment) is a major threat to the control over TB. This study aimed to investigate the association of smoking and drug abuse with 
treatment failure among individuals with TB.
Material and methods: Out of 286 TB patients with available data registered by the health system of Hamadan Provinces in 
western Iran, 24 TB patients with treatment failure (positive sputum smear, 5 months after initiation of anti-TB treatment) and 
262 patients without treatment failure (negative sputum smear, five months after initiation of anti-TB treatment) were selected 
as case and control groups, respectively. These two groups were compared to each other in terms of demographic status which 
include age, sex, job, residence, and risk factors such as smoking and drug abuse status. An odds ratio (OR) with a 95% confi-
dence interval was used as a measure of association. The Bonferroni correction was used to counteract multiple comparisons, 
therefore, a p-value of less than 0.004 was statistically significant. 
Results: No significant association was found between treatment failure and age, residence, comorbidity, education level, job 
status, sex, smoking, and method of drug abuse (P > 0.004). However, a significant association was found between duration of 
smoking, number of cigarettes per day, and drug abuse with treatment failure in univariate analysis (P < 0.004). In multivariate 
analysis, only an association with drug abuse was significantly associated with treatment failure (P = 0.047). 
Conclusion: Drug abuse substantially increases the risk of treatment failure. Therefore, in order to control TB, it is suggested that 
preventive programs are designed in order to decrease drug abuse among TB patients before starting treatment.
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Introduction
Tuberculosis (TB) is a contagious and air-
borne disease caused mainly by Mycobacterium 
tuberculosis, but also rarely by Mycobacterium 
bovis and africanum [1]. Many of the health and 
medical interventions used to control TB have 
resulted in a remarkable reduction of the disease 
over recent decades [2]. Despite this substantial 
progress against TB, it has remained as one of ten 
major causes of death in the world. Based on the 
global tuberculosis report of 2018 conducted by 
the World Health Organization (WHO), 10 million 
people developed TB disease and 1.3 million 
people died from TB [3, 4]. In addition, the re-
port reveals that 90% of cases of TB and deaths 
due to the disease occur in developing countries 
[5]. Moreover, the studies report that nearly one-
third of the world’s population is infected with 
tuberculosis [6, 7]. 
Many risk factors have been identified that 
increase the risk of developing TB. Poverty, HIV 
infection, substance abuse, alcohol consumption, 
silicosis, diabetes mellitus, severe kidney disease, 
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low body weight, organ transplants, and head 
and neck cancers are examples of risk factors 
that are confirmed to increase the risk of being 
infected with TB [8–11]. Therefore, preventing 
and removing these risk factors may decrease the 
prevalence of TB remarkably.
The WHO’s recommended strategy for con-
trolling TB is via treatment of patients using 
the DOTS (Directly Observed Treatment, Short-
course) program [12]. As the WHO claims, “the 
most cost-effective way to stop the spread of TB 
in communities with a high incidence is by cur-
ing it” [13]. This strategy has five elements that 
include government commitment, case detection, 
treatment regimen, standardized recording, and 
a structured reporting system. The major threat to 
this strategy is treatment failure of TB [14]. Treat-
ment failure occurs in patients who, five months 
after initiation of anti-TB treatment, have positive 
sputum smears [15]. Treatment failure increases 
the probability of drug resistance and may result 
in the spread of TB.  Several factors contribute 
to treatment failure such as age, sex, education 
level, alcohol consumption, HIV, and weight loss 
[16-19]. Another two suspected risk factors that 
may have a role in treatment failure are smoking 
and drug abuse. However, findings on these two 
risk factors are not clarified well, and results are 
contradictory. While some studies confirm ex-
istence of an association between smoking and 
drug abuse with treatment [20], other studies did 
not endorse such an association [21]. Reaching 
a consensus on this issue requires more research. 
Therefore, in this study, we aimed to investigate 
the identity and existence of this association 
between smoking and drug abuse with treatment 
failure of TB in Hamadan province, western Iran. 
Material and methods
Type of study
This study was a case-control study. 
Setting and population
The study was conducted in Hamadan prov-
ince, western Iran. The study population included 
all patients with confirmed tuberculosis who were 
registered by the health system of the province 
from 2010 to 2018 and who underwent anti-TB 
treatment. Based on the Iranian national guide-
lines for the control of TB, sputum smear micros-
copy (SSM) was used to diagnose TB in patients. 
After confirmation of TB in individuals, they 
underwent directly observed treatment based on 
the short-course (DOTS) program. However, if 
positive sputum smear results remained 5 months 
after the initiation of treatment, the result was 
labelled treatment failure. Accordingly, in this 
case-control study, we defined the case group 
(with treatment failure) as TB patients who, five 
months after initiation of anti-TB treatment, had 
positive sputum smear results. On the other hand, 
we defined the control group as TB patients who, 
5 months after initiation of anti-TB treatment, 
had negative sputum smears. In the case that 
the patients died before completion of treatment 
course, or if there was no available data, they 
were excluded from the study. Accordingly, out 
of 321 patients registered by the system, 24 had 
treatment failure (case) and 262 patients were 
without treatment failure (control) and with 
available data included in the study. Thirty-five 
patients were excluded from the study because 
there was no data available for them.
Variables
According to data registered by the system, 
variables of this study included age, sex, educa-
tion level, job, residence, comorbidity, family his-
tory of TB, smoking status, number of cigarettes 
per day, duration of smoking, drug abuse status, 
and type of drug abuse. For this study, we defined 
a “smoker” as an individual who smokes at least 
one cigarette every day.
Statistical analysis
We used bivariate analysis including ANOVA 
and the chi-square test to assess the difference 
between case and control groups. Moreover, we 
used logistic regression to adjust the confounding 
effect of other variables. An odds ratio with a 95% 
confidence interval was used as a measure of as-
sociation. Further, in order to deal with multiple 
comparison problems in the tests, we used the 
Bonferroni correction to adjust the p-value. There-
fore, a p-value less than 0.004 was statistically sig-
nificant. The Hosmer and Lemeshow test was used 
to verify goodness of fit for the regression model.
Ethical considerations
The study has been registered by the Ethics 
Committee of Hamadan University of Medical 
Sciences (NO. IR.UMSHA.REC.1397.498). Fur-
thermore, all information collected was consid-
ered as confidential.
Results 
Out of the 321 registered patients who un-
derwent anti-TB treatment, data for 286 patients 
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was available. Five months after initiation of 
anti-TB treatment, sputum results were positive 
for 24 patients and negative for 262 patients (con-
trol group). Out of 35 patients that were without 
data for analysis, 28 patients (80%) died before 
completion of the treatment course. Moreover, 
data for the outcome of seven patients was not 
retrievable. 
Table 1 demonstrates the demographic and 
risk factor characteristics for the case and control 
groups. As shown in the table, despite 75% of 
the case group and 48.5% of the control group 
being men, the p-value, according to the Bonfer-
roni correction, was less than 0.01. Therefore, 
sex difference between case and control group 
was not statistically significant at a level of 
0.004. Moreover, we did not find a significant 
difference between two groups in terms of age, 
education, job, residence, family history of TB, 
and co-morbidity (p > 0.004). 
In terms of smoking, results presented in 
table 1 showed that the percentage of smokers 
in case groups is substantially higher than in the 
control group (58% vs 35%). In other words, the 
odds of patients being smokers was 2.58 times 
higher in the case group than in the control group. 
However, this difference was not statistically 
significant at a level p > 0.004. The duration of 
smoking was significantly associated with treat-
ment failure (p = 0.001). Moreover, patients in 
the case group smoked on average eight cigarettes 
per day more than patients in the control group 
(p < 0.001). In terms of duration of smoking, 
the mean duration of smoking in the case group 





Mean (SD) age [year] 54 ± 20.9 53.6 ± 20.6 ANOVA [F (1,284) =  0.008, p = 0.93)]
Mean (SD) duration of smoking [year] 17.7 ± 14.3 9.4 ± 13.3 ANOVA [F (1,284) = 8.54, p = 0.004)]
Mean (SD) cigarettes smoked per day [number] 14.7 ± 11.4 6.4 ± 9.4 ANOVA [F (1,276) = 15.86, p = < 0.001)]
Male 18 (75%) 127 (48.5%) 0.01
Education level
0.33
    Illiterate 5 (20.7%) 71 (27.1%)
    Primary 4 (16.7%) 55 (21%)
    Guidance school 10 (41.7%) 70 (26.7%)
    High school 1 (4.2%) 38 (14.5%)
    Diploma and more 4 (16.7%) 28 (10.7%)
Urban 16 (66.7%) 167 (63.7%)
Job status
0.17
    Employee 2 (8.3%) 29 (11.1%)
    Worker 0 (0%) 28 (3.1%)
    Housewife 5 (20.8%) 105 (40 %)
    Freelance 9 (37.5%) 55 (21%)
    Unemployed 3 (12.5%) 6 (2.3%)
    Student 1 (4.2%) 12 (4.5%)
    Other 4 (16.7%) 47 (18%)
Family history of TB 5 (20.8%) 64 (24.5%) 0.95
Comorbidity 6 (25%) 55 (21%) 0.16
Smoker 14 (58.3%) 92 (35%) 0.02
Drug abuser 11 (45.8%) 57 (21.8%) 0.001
Drug abuse method
0.32
    Swallowing 1 (7.3%) 21 (37.6%)
    Injection 8 (57%) 12 (21.4%)
    Inhalation 5 (35.7%) 23 (41%)
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low body weight, organ transplants, and head 
and neck cancers are examples of risk factors 
that are confirmed to increase the risk of being 
infected with TB [8–11]. Therefore, preventing 
and removing these risk factors may decrease the 
prevalence of TB remarkably.
The WHO’s recommended strategy for con-
trolling TB is via treatment of patients using 
the DOTS (Directly Observed Treatment, Short-
course) program [12]. As the WHO claims, “the 
most cost-effective way to stop the spread of TB 
in communities with a high incidence is by cur-
ing it” [13]. This strategy has five elements that 
include government commitment, case detection, 
treatment regimen, standardized recording, and 
a structured reporting system. The major threat to 
this strategy is treatment failure of TB [14]. Treat-
ment failure occurs in patients who, five months 
after initiation of anti-TB treatment, have positive 
sputum smears [15]. Treatment failure increases 
the probability of drug resistance and may result 
in the spread of TB.  Several factors contribute 
to treatment failure such as age, sex, education 
level, alcohol consumption, HIV, and weight loss 
[16-19]. Another two suspected risk factors that 
may have a role in treatment failure are smoking 
and drug abuse. However, findings on these two 
risk factors are not clarified well, and results are 
contradictory. While some studies confirm ex-
istence of an association between smoking and 
drug abuse with treatment [20], other studies did 
not endorse such an association [21]. Reaching 
a consensus on this issue requires more research. 
Therefore, in this study, we aimed to investigate 
the identity and existence of this association 
between smoking and drug abuse with treatment 
failure of TB in Hamadan province, western Iran. 
Material and methods
Type of study
This study was a case-control study. 
Setting and population
The study was conducted in Hamadan prov-
ince, western Iran. The study population included 
all patients with confirmed tuberculosis who were 
registered by the health system of the province 
from 2010 to 2018 and who underwent anti-TB 
treatment. Based on the Iranian national guide-
lines for the control of TB, sputum smear micros-
copy (SSM) was used to diagnose TB in patients. 
After confirmation of TB in individuals, they 
underwent directly observed treatment based on 
the short-course (DOTS) program. However, if 
positive sputum smear results remained 5 months 
after the initiation of treatment, the result was 
labelled treatment failure. Accordingly, in this 
case-control study, we defined the case group 
(with treatment failure) as TB patients who, five 
months after initiation of anti-TB treatment, had 
positive sputum smear results. On the other hand, 
we defined the control group as TB patients who, 
5 months after initiation of anti-TB treatment, 
had negative sputum smears. In the case that 
the patients died before completion of treatment 
course, or if there was no available data, they 
were excluded from the study. Accordingly, out 
of 321 patients registered by the system, 24 had 
treatment failure (case) and 262 patients were 
without treatment failure (control) and with 
available data included in the study. Thirty-five 
patients were excluded from the study because 
there was no data available for them.
Variables
According to data registered by the system, 
variables of this study included age, sex, educa-
tion level, job, residence, comorbidity, family his-
tory of TB, smoking status, number of cigarettes 
per day, duration of smoking, drug abuse status, 
and type of drug abuse. For this study, we defined 
a “smoker” as an individual who smokes at least 
one cigarette every day.
Statistical analysis
We used bivariate analysis including ANOVA 
and the chi-square test to assess the difference 
between case and control groups. Moreover, we 
used logistic regression to adjust the confounding 
effect of other variables. An odds ratio with a 95% 
confidence interval was used as a measure of as-
sociation. Further, in order to deal with multiple 
comparison problems in the tests, we used the 
Bonferroni correction to adjust the p-value. There-
fore, a p-value less than 0.004 was statistically sig-
nificant. The Hosmer and Lemeshow test was used 
to verify goodness of fit for the regression model.
Ethical considerations
The study has been registered by the Ethics 
Committee of Hamadan University of Medical 
Sciences (NO. IR.UMSHA.REC.1397.498). Fur-
thermore, all information collected was consid-
ered as confidential.
Results 
Out of the 321 registered patients who un-
derwent anti-TB treatment, data for 286 patients 
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was eight years longer than in the control group, 
which was statistically significant (p = 0.004).
In terms of drug abuse status, as demon-
strated In table 1, we found that 46% of patients 
in the case group and 22% in the control group 
were drug abusers. Therefore, drug abusers were 
4 times more likely to have treatment failure 
(p < 0.001). However, when investigating the 
method of drug abuse between the two groups, 
the method of abuse did not result in a significant 
difference (p = 0.32).
To adjust for the confounding effect of the 
variables, we used logistic regression. As shown 
in Table 2, only drug abuse is significantly asso-
ciated with treatment failure in TB patients, with 
a 3 times greater likelihood that failure occurs 
(p = 0.047). The result of the Hosmer and Leme-
show test for goodness of fit for logistic regres-
sion models was not significant, which means 
that the model is a good fit (Chi-square = 3.08, 
df = 8, p = 0.93).
Discussion 
In this study, we aimed to explore the associ-
ation of smoking and drug abuse with treatment 
failure in TB patients (defined as a positive 
sputum smear five months after the initiation of 
treatment). Our study showed that drug abuse was 
significantly associated with treatment failure. 
Although the failure rate among smokers and drug 
abusers was higher than non-smokers and drug 
abusers, after adjusting for the effects of other 
factors, only the effect of drug abuse remained as 
significant (increasing the risk of treatment failure 
by 3.5 times). This result reveals the major effect 
of drug abuse on treatment failure. Although we 
did not observe a significant association between 
smoking and treatment failure in multivariate 
analysis, it seems that this association exists. The 
most important reason for a lack of association 
between smoking and treatment failure in our 
study was our small sample size (low power of 
study). However, there is significant evidence for 
this association being present in our study. In this 
study, we investigated the association between 
the number of cigarettes smoked per day and 
duration of smoking with treatment failure. We 
found that a significant association exists between 
them seeing as the number of cigarettes per day 
and duration of smoking was substantially higher 
in patients with treatment failure than patients 
without treatment failure. In epidemiology, this 
issue is called “dose–response relationship” [22], 
which is one of the major criteria for a causal 
association to be made between an exposure and 
an outcome of interest. In addition, given that 
data for smoking and drug abuse was collected 
before the initiation of treatment, another crite-
rion of causality which is called “temporality” is 
likely established [22]. This criterion is the most 
important factor for establishing causality in 
epidemiology. Another criterion for establishing 
causality is identifying a consistency of findings 
[22]. The majority of previous studies confirmed 
our results.  In a cohort study in Peru, it was 
found that both smoking and drug abuse were 
significantly associated with treatment failure, 
and that the effect of drug abuse was stronger than 
the effect of smoking. The paper recommended 
identifying smokers and drug abusers before 
initiating treatment to increase the probability 
of treatment success of TB [23]. In addition, in 
a study conducted in Brazil aimed to examine 
the role of drug abuse as a predictor of treatment 
failure, it was reported that 33% of drug abusers 
and 7% of non-drug abusers had treatment failure. 
Our study had similar results showing that about 
34.8% of smokers and 12.5% of non-smokers had 
treatment failure [24]. However, some studies 
did not find a significant association between 
smoking and drug abuse with treatment fail-
ure. For example, El-Shabrawy et al found that, 
despite a high rate of treatment failure in smokers 
compared with non-smokers, no significant asso-
ciation between smoking and treatment failure 
Table 2. Logistic regression analyses of factors associated with treatment failure in TB patients
Variable Crude odds ratio (95% CI) p-value Adjusted odds ratio (95%CI) p-value
Age 1 (0.98,1.02) 0.93 1 (0.98–1.02) 0.79
Sex 3.2 (1.22,8.2) 0.02 1.55 (0.45–5.31) 0.48
Smoker 2.58 (1.1, 6.1 0.02 1.26 (0.42–3.76) 0.67
Drug abuser 4.2 (1.8, 9.95) 0.001 2.98 (1.02–7.14) 0.047
Constant — — 1.210 0.84
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existed [21]. Apparently, a small sample size of 
their study was the main reason for this result. 
Further, Alo in Fiji did not observe a significant 
association between smoking status and treatment 
failure [25]. However, despite these contradictory 
results, the existence of an association is likely. 
To properly explain these differing results, we 
recommend performing a meta-analysis since 
there is evidence indicating that there is an as-
sociation between drug abuse and smoking with 
treatment failure.
With consideration to the association be-
tween smoking and drug abuse with treatment 
failure and the global prevalence of smoking 
(20%) and drug abuse (2%) in the world [26–28], 
especially in low and middle-income countries 
where the prevalence of TB is high, it will be very 
difficult to control the spread of TB [29]. Many 
studies show that the prevalence of smoking and 
drug abuse among TB patients is a critical aspect 
of disease control. In a study by Burnet, the es-
timated prevalence of smoking in patients with 
active and latent infection was 56% and 60%, 
respectively[30]. Therefore, this high prevalence 
of smoking in TB patients results in treatment 
failure and eventually, death. In addition, failure 
to properly control TB increases the spread of 
TB in the population. It is also important to note 
the role of drug abuse and the AIDS epidemic as 
important factors in the spread of TB [31, 32]. 
Literature explains the mechanisms of how 
smoking and drug abuse affect treatment failure. 
It seems that two likely pathways exist for how 
smoking and drug abuse influence the treatment 
outcome. The studies reveal that an interaction 
of TB with smoking and drug abuse exists at 
a cellular level and may result in a decreased 
level of immunity through reduction in activity 
of macrophages, dendritic cells, and natural killer 
cells [33].  Moreover, studies demonstrated that 
smoking and drug abuse are associated with a low 
adherence to treatment in male TB patients [34]. 
This study has two messages to policy-mak-
ers: Firstly, statistics regarding the high amount 
of patients with treatment failure in TB is re-
markable. As noted before, treatment failure is 
the biggest threat for the control of TB and, as 
such, paying special attention to treatment failure 
is necessary. Secondly, smoking and drug abuse 
showed a significant effect on treatment failure, 
and this has been reciprocated by many other 
studies which also confirm this issue. Therefore, 
it is recommended to design programs for the ces-
sation of smoking and drug abuse before initiating 
treatment of TB.
This study has limitations. Firstly, sample 
size, especially in our case group, is small. Small 
sample size may reduce the power of study to 
detect significant differences. This issue is one of 
the determinants for a non-significant association 
between smoking and treatment failure. Secondly, 
we used data registered by the TB system which 
is known to have problems in accuracy and in 
incomplete registrations. Thirdly, we could not 
obtain some important information such as per-
centage of multidrug resistance and HIV disease 
status among TB patients. This information may 
present a more clarified picture of the TB patients 
we studied. Fourthly, a number of the patients 
died or were lost to follow up before completion 
of the treatment course. Therefore, we performed 
our analysis only on patients who survived, 
which may have led to selection bias affecting our 
final result. Based on these limitations, designing 
a prospective cohort with an accurate registration 
of information and with interventional studies 
to assess the effectiveness of smoking and drug 
abuse cessation programs on treatment failure is 
recommended.
Conclusion
Our results confirm that drug abuse is associ-
ated with treatment failure in TB patients. How-
ever, smoking significantly increased the risk of 
treatment failure as well. Therefore, it suggested 
that cessation of smoking and drug abuse accom-
pany the initiation of treatment programs for TB 
patients. Training health workers to be able to 
detect smokers and drug abusers should also be 
incorporated into treatment programs to increase 
the efficacy of TB treatment.  
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